Zura Bio Limited
ZURAZura Bio Limited is a clinical-stage biotechnology company focused on developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases.
Table of contents
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Zura Bio Limited is a clinical-stage biotechnology company focused on developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases. The company identifies immune-mediated diseases where translational and clinical evidence supports specific biological pathways, targeting conditions with significant unmet medical needs. Its core strategy involves advancing multi-target and single-target antibody-based therapies to achieve durable disease control.
A clinical-stage developer of differentiated bispecific and monoclonal antibodies targeting IL-17A, BAFF, IL-7Rα, and IL-33 pathways.
Questions, answered.
- What is Zura Bio Limited's market cap?
- Zura Bio Limited (ZURA) has a market capitalization of $511.1M and trades on NASDAQ.
- Who are Zura Bio Limited's competitors?
- Zura Bio Limited's key competitors include AbbVie Inc., Amgen Inc., Zenas BioPharma, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Zura Bio Limited partner with?
- Zura Bio Limited's notable partners include Eli Lilly and Company, Pfizer Inc., Lonza Sales AG, and others.
- What subsidiaries does Zura Bio Limited have?
- Zura Bio Limited's subsidiaries include ZB17 LLC, Z33 Bio Inc., Zura Bio UK.
- Where is Zura Bio Limited headquartered?
- Zura Bio Limited is headquartered in United States of America and employs approximately 15 people. It has been publicly traded since 2023.